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ABSTRACT
Targeted gene addition to mammalian genomes is
central to biotechnology, basic research and gene
therapy. For example, gene targeting to the
ROSA26 locus by homologous recombination in
embryonic stem cells is commonly used for mouse
transgenesis to achieve ubiquitous and persistent
transgene expression. However, conventional
methods are not readily adaptable to gene targeting
in other cell types. The emerging zinc finger
nuclease (ZFN) technology facilitates gene targeting
in diverse species and cell types, but an optimal
strategy for engineering highly active ZFNs is still
unclear. We used a modular assembly approach to
build ZFNs that target the ROSA26 locus. ZFN
activity was dependent on the number of modules
in each zinc finger array. The ZFNs were active in a
variety of cell types in a time- and dose-dependent
manner. The ZFNs directed gene addition to the
ROSA26 locus, which enhanced the level of
sustained gene expression, the uniformity of gene
expression within clonal cell populations and the
reproducibility of gene expression between clones.
These ZFNs are a promising resource for cell engin-
eering, mouse transgenesis and pre-clinical gene
therapy studies. Furthermore, this characterization
of the modular assembly method provides general
insights into the implementation of the ZFN
technology.
INTRODUCTION
New genes are routinely introduced to mammalian cells
for studies related to functional genomics, cell biology,
proteomics, cell-based drug discovery and many other
applications in biotechnology and basic science. Most
methods for the stable introduction of genes into mamma-
lian cells rely on random integration of the transgene into
the genome followed by drug selection and laborious
screening to identify cell populations expressing the
transgene at desirable levels. This uncontrolled nature of
random transgene integration can lead to several con-
founding effects on gene expression, including multiple
integrations per cell, the activation or disruption of
endogenous genes at or near the site of integration, and
unstable expression of the transgene due to epigenetic
regulation. These characteristics of stable cell line
engineering often lead to unpredictable cell behavior, irre-
producible results and possible erroneous data interpret-
ation. Technologies that facilitate the precise addition of
transgenes to speciﬁc locations of mammalian genomes
have the potential to address these limitations.
Homologous recombination (HR) is a mechanism by
which precise changes to deﬁned genomic sequences can
be introduced (1,2). Gene targeting by HR, combined with
stringent selection methods, is commonly used in mouse
embryonic stem cells to generate transgenic mice (1,2).
Gene targeting to the mouse ROSA26 locus by HR is
the preferred method for mouse transgenesis as this site
provides improved targeting efﬁciency and ubiquitous
transgene expression (3,4). Furthermore, gene addition
to this locus does not have any adverse consequences on
mouse viability or cell phenotype. The mouse ROSA26
locus has a long history of development and application
in mouse genetics. Mice modiﬁed at the ROSA26 locus
were initially derived from pools of embryonic stem cells
infected with a retroviral gene trap (5). The ROSA26 locus
was cloned and shown to encode a nuclear RNA expressed
in a broad variety of tissues (3). The generalized expres-
sion at this site suggested that gene targeting to the
ROSA26 locus would be a desirable method to achieve
ubiquitous transgene expression. From the time of its
discovery, hundreds of transgenic animals and cell lines
expressing a variety of transgenes including reporters,
site-speciﬁc recombinases, and non-coding RNAs have
been successfully created using the ROSA26 locus.
However, conventional HR methods are not readily
transferable to gene targeting in non-embryonic stem
cells from mice or in cells from other species.
Consequently, the creation of gene-targeted lineage-
committed cell types has traditionally required targeting
mouse embryonic stem cells followed by directed differen-
tiation into the cell type of interest or generating
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be harvested. Technologies for gene targeting in somatic
cells and established cell lines would circumvent these
costly, inefﬁcient and laborious steps.
Two discoveries have opened new venues toward
achieving high rates of HR in mammalian somatic cells.
The ﬁrst was the discovery that the introduction of
double-strand breaks at genomic target sites increases
the rate of HR at that site by several orders of magnitude
(6). The second was the development of engineered zinc
ﬁnger nucleases (ZFNs), which are able to generate
site-speciﬁc double-strand breaks at targeted genome
sequences (7–9). Synthetic custom-designed ZFNs are a
fusion of a DNA-binding domain consisting of an array
of individual zinc ﬁnger motifs and the non-speciﬁc cata-
lytic domain of the FokI restriction endonuclease. Each
zinc ﬁnger recognizes  3 consecutive base pairs of DNA
(10). The speciﬁcity of particular zinc ﬁngers has been
examined extensively through site-directed mutagenesis
and rational design (11,12) or the selection of large
combinatorial libraries (13–18). Through this work, syn-
thetic zinc ﬁnger domains have been established that bind
to almost any nucleotide triplet (19–21). Signiﬁcantly, the
modular structure of the zinc ﬁnger motif permits the con-
junction of several domains in series, allowing for the rec-
ognition and targeting of extended sequences in multiples
of 3nt (22).
The cleavage of DNA by ZFNs can theoretically be
targeted to nearly any given sequence in the genome
based on the DNA-binding speciﬁcity of the zinc ﬁnger
domains (23–25). These targeted double-strand breaks can
be repaired by the error-prone, non-homologous
end-joining (NHEJ) pathway or HR. DNA breaks
repaired by NHEJ frequently exhibit nucleotide deletions
and insertions at the cleavage site. This approach can be
used to knockout genes in many model organisms,
including mice, by expression of ZFNs in early embryos
(26–30). However, when a donor repair template is
provided with the ZFNs, the rate of HR at the break
site is dramatically enhanced (9,23,25). Following this
principle, ZFNs have been used to achieve efﬁcient gene
targeting at various endogenous genomic loci in mamma-
lian cells (23,31–35).
Several approaches have been described for designing,
selecting, and assembling the zinc ﬁnger domains that
confer targeting speciﬁcity to ZFNs (18,36–43). One of
the easiest and most straightforward design protocols
involves the modular assembly of zinc ﬁnger arrays
based on speciﬁc zinc ﬁngers that have been previously
identiﬁed to bind certain 3bp sequences (39,40). Alter-
natively, selection-based methods have been described in
which novel zinc ﬁnger arrays are isolated from large
libraries (18). Although this approach is signiﬁcantly
more complex and labor-intensive, it has been reported
to generate active ZFNs at a much higher frequency
than the modular assembly strategy (44). The recently
described context-dependent modular assembly (CoDA)
method provides an appealing balance of these two
approaches (41). In contrast to these ‘open-source’
methods, the most prevalent approach to generating
highly active ZFNs targeted to endogenous mammalian
genes is a proprietary method developed by scientists at
Sangamo Biosciences (25). In fact, ZFNs targeted to the
ROSA26 locus and designed by these proprietary methods
have recently been reported (29). Although all of these
approaches have been used to assemble active ZFNs,
there are still many uncertainties regarding the optimal
criteria for ZFN design and assembly.
To further evaluate the efﬁcacy of publicly available
ZFN assembly methods, we generated ZFNs by modular
assembly (39,40) that target the identical sequence of the
ROSA26 locus previously reported to be targeted by pro-
prietary ZFNs (29,45). Importantly, although the target
site of this ZFN was described, the sequence of the ZFN
was not reported. Our novel ZFN pairs created by
modular assembly efﬁciently induce double-strand
breaks at the ROSA26 locus in a variety of murine cell
lines. ZFN activity was dependent on the number of zinc
ﬁngers on the ZFN proteins, time, the ZFN dose, and cell
type. A donor vector was constructed that contains a
transgene expression cassette ﬂanked by two 800-bp
homology arms. When delivered alone, this donor vector
integrated randomly into the genome. However, when
delivered in conjunction with the ZFN pair targeting the
ROSA26 locus, transgene integration at the desired target
site was readily detected in selected and unselected cell
populations. Targeted transgene expression was relatively
uniform amongst clonal cell populations, whereas random
plasmid integration led to highly variable levels of expres-
sion. Collectively, these results provide insights into
strategies and criteria for ZFN design and assembly and
characterize a method for gene targeting in murine cell
lines that will enable diverse areas of research.
MATERIALS AND METHODS
Cell culture and electroporation
NIH3T3, 293T, C2C12 and Neuro2A cells were obtained
from the American Tissue Collection Center (ATCC)
through the Duke University Cancer Center Facilities.
NIH3T3 cells were maintained in DMEM supplemented
with 10% bovine calf serum and 1% penicillin/strepto-
mycin. 293T and Neuro2A cells were maintained in
DMEM supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin. C2C12 cells were maintained
in DMEM supplemented with 20% fetal bovine
serum and 1% penicillin/streptomycin. These cell lines
were maintained at 37 C and 5% CO2. Primary skeletal
myoblasts, provided by Dr. Terence A. Partridge, were
isolated from H-2K
b-tsA58 transgenic mice harboring a
thermolabile mutant of the immortalizing SV40 large
T antigen under the control of an interferon-gamma indu-
cible promoter (46). These cells were grown in DMEM
supplemented with 20% fetal bovine serum, 2% chick
embryo extract (Accurate Chemical), 2% L-glutamine,
20U/ml g-interferon and 1% penicillin/streptomycin on
tissue culture dishes coated with 0.01% porcine gelatin
and maintained at 33 C and 5% CO2. Cell culture
reagents were obtained from Invitrogen unless stated
otherwise.
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2000 (Invitrogen) according to manufacturer’s instruc-
tions in 6-well plates with 2ml of OPTI-MEM. Plasmid
DNA was delivered to all other cell lines by electropor-
ation with a Gene Pulser Xcell System (BioRad).
Two million cells were electroporated in 400ml of OPTI-
MEM, using conditions optimized for each cell line.
Electroporation efﬁciencies were routinely >90% in
Neuro2A cells and primary myoblasts, 80% in C2C12
cells, and 70% in NIH3T3 cells, as determined by ﬂow
cytometry following delivery of an EGFP expression
plasmid. Unless indicated otherwise, the amount of
DNA used for electroporation was 10mg of each ZFN
or empty control expression vector and 40mg of donor
vector.
Plasmids and ZFN assembly
The ZFN expression plasmid (pCMV) was provided by
David J. Segal. FokI domains containing both the ELD/
KKR obligate heterodimer mutations (47) and the
Sharkey mutations (48) were synthesized and codon
optimized by Bio Basic. The zinc ﬁnger modules were
provided by Carlos F. Barbas, III and ZFNs were
designed and assembled as previously described (39,40).
Full ZFN sequences are provided in the online
Supplementary Information. The homology arms in the
ROSA26 donor vector were generated by PCR of mouse
genomic DNA and insertion of the PCR-ampliﬁed right
homology arm (left primer: 50-TTATTGCGGCCGCAG
ATGGGCGGGAGTCTTCT-30, right primer: 50-AACA
CCGCGGCAGTTTATAAATGGAGAAAAAGGAGA
-30) between the NotI and SacII sites and the left homology
arm (left primer: 50-TCTATGGTACCAGTTAACGGCA
GCCGGAGT-30, right primer: 50-CGGACGAATTCTCT
AGAAAGACTGGAGTTGCAGA-30) between the KpnI
and EcoRI sites in the pZDonor AAVS1 vector obtained
from Sigma–Aldrich.
Single-strand annealing recombination assay
Single-strand annealing (SSA) plasmids were provided by
David J. Segal (49). A gene encoding EGFP was divided
into two segments, which were separated by a stop codon
and a ROSA26 ZFN target site. Both EGFP segments
contained a 275bp homology region. Upon cleavage at
the ZFN target site, the cellular SSA repair mechanisms
remove the stop codon and restore the wt EGFP cDNA
(49). Therefore EGFP expression provides a quantitative
measurement of ZFN activity. For episomal SSA assays,
ZFN expression plasmids and SSA reporters were co-
transfected into 293T cells. For genomic SSA assays, the
SSA-EGFP open reading frame was cloned into the
pcDNA5-FRT vector, which was integrated in a single
site of the genome of 293 Flp-In cells (Invitrogen) accord-
ing to the manufacturer’s instructions. The number of
EGFP-positive cells was measured by ﬂow cytometry.
Quantiﬁcation of DNA repair
ZFN-mediated DNA cleavage was measured by quantify-
ing the mutations created at the target site that result from
double-strand break repair via NHEJ (50). Following
electroporation, the cells were maintained at 32 C for
3 days, which has been shown to enhance the activity of
the ZFNs (51), and the genomic DNA was isolated from
ZFN-treated cells using the DNeasy kit (Qiagen). The
region surrounding the ZFN target site was ampliﬁed by
PCR with the AccuPrime PCR kit (Invitrogen) and
50–200ng of genomic DNA as template with primers
50-AAGGGAGCTGCAGTGGAGTA-30 and 50-GCGG
GAGAAATGGATATGAA-30. For NIH3T3 and C2C12
cells the primers were 50-GCACGTTTCCGACTTGAG
TT-30 and 50-GGCGGATCACAAGCAATAAT-30. The
PCR products were melted and reannealed using the tem-
perature program: 95 C for 180s, 85 C for 20s, 75 C for
20s, 65 C for 20s, 55 C for 20s, 45 C for 20s, 35 C for
20s and 25 C for 20s with a 0.1 C/s decrease rate in
between steps. This allows the formation of mutant and
wild-type DNA strands with the consequent formation of
distorted duplex DNA. Eighteen microliters of the
reannealed duplex was combined with 2ml of the
Surveyor nuclease (Transgenomic), which cleaves DNA
duplexes at the sites of distortions created by either
bulges or mismatches (52), and 1ml of enhancer solution.
This reaction was incubated at 42 C for 60min and then
separated on a 10% TBE polyacrylamide gel. The gels
were stained with ethidium bromide and quantiﬁed using
ImageLab (BioRad) according to the procedure described
by Guschin et al. (50). The limit of detection of this assay
has been estimated to be  3% modiﬁed alleles (52).
PCR-based detection of HR events
Neuro2A cells were electroporated with 10mg of each
ZFN and 40mg of the donor vector. After 4 days
genomic DNA was isolated using the DNeasy kit
(Qiagen). The targeted region was ampliﬁed by PCR
with the AccuPrime PCR kit (Invitrogen) and 50–200ng
of genomic DNA as template. For the detection of
Zeo-EGFP integration, the primers used were: 50-CTTC
TAGTTGCCAGCCATCTG-30 and 50-TCAGGTAATA
TTGGGGGAGGAGAC-30 and the cycling program
was 95.5 C for 8min followed by 40 cycles of 95.5 C for
20s, 55 C for 30s, and 68 C for 100s. For detection of
MCS integration, the primers used were 50-GAAATATTC
TCGAGGTTTAAACGTC-30 and 50-GGTAATATTGG
GGGAGGAGACATC-30 and the cycling program was
95.5 C for 8min followed by 40 cycles of 95.5 C for
20s, 53 C for 30s, and 68 C for 70s.
Clonal analysis
Four days after electroporation with the Zeocin
R-EGFP
donor alone or in combination with ZFNs, Neuro2A
cells were selected with 1mgml
 1 Zeocin
TM for 14 days.
Colonies were isolated and expanded for 7 additional
days. Targeted integration events in the established cell
lines were identiﬁed by PCR as described above and
levels of Zeocin
R-EGFP expression were measured by
ﬂow cytometry. Data was analyzed with the FlowJo
software package.
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SSA assays were performed in duplicate in three independ-
ent experiments (n=3). Data shown are the average of all
data points±standard deviation. Other ﬁgures show
representative data of experiments performed at least
three times. Statistical analysis for Figures 2B, C and 6B
was performed using one-way analysis of variance
(ANOVA) with a=0.05 and two-sample Student’s t test
assuming equal variances. Statistical analyses were per-
formed with Microsoft Ofﬁce Excel.
RESULTS
Design and construction of ZFNs targeted
to ROSA26
We designed novel ZFNs targeted to a previously reported
ZFN target site in the ROSA26 locus (Figure 1A) (29).
Our ZFNs were generated following a well-characterized
modular assembly approach (39,40). Because ZFNs act as
dimers (Figure 1A), two zinc ﬁnger protein arrays were
assembled using an archive of zinc ﬁnger DNA-binding
modules (39,40). One array consists of six zinc ﬁnger
domains (designated the left, or L6 array) and the other
array consisted of four zinc ﬁnger domains (designated
the right, or R4 array) (Figure 1B). These arrays were
coupled to either the wild-type DNA cleavage domain
of the type IIS restriction enzyme FokI or a
codon-optimized FokI domain containing mutations
shown to prevent homodimer formation (Q486E, I499L,
N496D in L6 and E490K, I538K and H537R in R4) (47).
The ‘Sharkey’ mutations S418P and K441E were also
added to both heterodimer FokI domains to enhance
cleavage activity (48,53). The complete sequence of both
ZFNs is provided in Supplementary Figures S1 and S2.
Activity of ROSA26 ZFNs in an episomal single-strand
annealing assay
Since the modular assembly strategy used here adds indi-
vidual zinc ﬁngers sequentially (40), we generated ZFNs
containing variable numbers of zinc ﬁnger modules
designated RXLY, where X refers to the number of zinc
ﬁngers on the right ZFN and Y refers to the number of
zinc ﬁngers on the left ZFN. We then tested whether
ROSA26 ZFNs R3L3, R3L4, R3L5, R3L6, R4L3,
R4L4, R4L5 and R4L6 were able to induce double
strand breaks at their target site in a mammalian cell-
based single-strand annealing (SSA) assay. In this assay,
a reporter vector containing two partially duplicated se-
quences of EGFP separated by a DNA sequence that
contains a stop codon and the ZFN target site is
cotransfected into 293 cells with vectors encoding the
ZFNs of interest. Double-strand breaks introduced in
the reporter vector by the ZFNs are repaired by the
endogenous cell repair machinery via the SSA mechanism,
thus eliminating the stop codon and restoring the EGFP
open reading frame (Figure 2A) (49,54).
Figure 1. Schematic representation of the genomic target sequence of the ROSA26 ZFNs. (A) Target sequence of the ROSA26 ZFNs. Located on
mouse chromosome 6, the Gt(ROSA)26Sor (ROSA26) locus spans 9kb at position 113,026,025 of NCBI Reference Sequence NC_000072.5. The
ROSA26 ZFN pair was generated by a modular assembly approach and consists of six zinc ﬁnger domains in the left array and four zinc ﬁnger
domains in the right array that target the ﬁrst intron of the ROSA26 locus. (B) Amino acid sequences of the alpha helices within the zinc ﬁnger
domains that recognize the indicated triplets of DNA.
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wild-type FokI domain was measured by ﬂow cytometry
to determine the percentage of EGFP-positive cells
compared to cells transfected with an SSA reporter
plasmid and control expression vector (Figure 2B). At
48h after transfection 17% of the cells transfected with
the R3L3 pair and 19% of cells transfected with R4L3
expressed EGFP. This represents a  2-fold increase over
background levels (8%). When the ZFN R3 was used, the
addition of extra modules to the left ZFN resulted in
notable increases in the number of cells expressing
EGFP: 28% for L4 (P=0.001 vs. L3), 38% for L5
(P=0.05 vs. L4) and 36% for L6. When ZFN R4 was
used, an increase in the number of EGFP-positive cells
was observed between L3 (19%) and L4 (32%)
(P=0.002) and L3 and L5 (38%) (P=0.001). Addition
of module L6 (36%) did not enhance ZFN activity in this
assay relative to L5.
Activity of ROSA26 ZFNs in a genomic SSA assay
The episomal SSA assay evaluates ZFN activity in the
context of many copies of the reporter plasmid within
each cell. To assess ZFN activity at a single and accessible
chromosomal locus, we created HEK293 human cell lines
in which the SSA reporter construct was stably integrated
into a deﬁned chromosomal locus using the Flp-In system
from Invitrogen. In the absence of ZFNs, spontaneous
EGFP gene reconstitution and protein expression was
detected in 0.3% of cells in two independent clonal popu-
lations. These cells were transfected with plasmids
encoding the ZFN pairs that were most active in the
episomal SSA assay, including R3L4, R3L5, R3L6,
R4L4, R4L5 and R4L6 (Figure 2C). The percentage of
cells expressing EGFP was determined by ﬂow cytometry.
The results show that only 0.9% of the cells transfected
with ZFN R3L4 expressed EGFP. Addition of the L5 and
L6 ZFN modules increased the percent of EGFP-positive
cells to 2.2% (P=1E-4 versus L4) and 3.4% (P=5E-5
versus L5), respectively. When the R4 ZFN module was
added to the R3L4 ZFN the number of GFP-positive cells
increased from 0.9% to 1.2%. Addition of the L5 and L6
modules increased the expression of EGFP to 3.2%
(P=2E-5 versus L4) and 3.7% (P=6E-5 versus L4),
respectively. These results suggest that the addition of
modules to the left ZFN generates greater ZFN activity.
Similarly, addition of the R4 module leads to enhanced
activity in the presence of the L4 (P=0.07) and L5
(P=0.006) modules. However, no signiﬁcant differences Figure 2. Activity of the ROSA26 ZFNs in SSA assays. (A) Schematic
representation of the vector used in Single Strand Annealing (SSA)
assays. A central region in the EGFP cDNA is duplicated and both
copies are separated by a sequence that introduces an early stop codon
to render a truncated not-functional EGFP. This spacer sequence also
contains the ROSA26 ZFN target site. Upon cleavage the endogenous
SSA repair mechanisms are expected to remove the stop codon and
restore the EGFP cDNA. (B) ROSA26 ZFNs efﬁciently induce
SSA-mediated gene repair in an episomal reporter plasmid.
Expression plasmids for ROSA26 ZFNs containing 3, 4, 5, or 6
modules in the left and right array were cotransfected with the SSA
reporter vector into 293T cells and the levels of EGFP expression were
measured at 48h by ﬂow cytometry (n=3, mean±stdev). ANOVA
P=2E-8. R3L4 versus R3L3 P=0.001; R3L5 versus R3L4 P=0.05;
Figure 2. Continued
R4L3 versus R4L4 P=0.002; R4L3 versus R4L5 P=0.001.
(C) ROSA26 ZFNs generate targeted genomic double-strand breaks.
The SSA reporter construct was stably integrated into the genome of
HEK293 cell lines. In the absence of ZFNs, spontaneous EGFP gene
reconstitution and protein expression was detected in 0.3% of cells.
Transfection of these cells with wild-type (WT) ZFNs or ZFNs con-
taining the obligate heterodimer and Sharkey mutations (eZFNs) led to
a signiﬁcant increase in the number of EGFP-positive cells (n=3,
mean±stdev). ANOVA P=7E-19. R3L5 versus R3L4 P=1E-4;
R3L6 versus R3L5 P=5E-5; R4L5 versus R4L4 P=2E-5; R4L6
versus R4L4 P=6E-5.
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used in this assay.
Off-target DNA cleavage by ZFNs can be caused by the
formation of homodimers of the left and right ZFN
(53,55). These effects can be signiﬁcantly reduced by
using FokI nuclease variants that are restricted to
forming heterodimers (47,53). Furthermore, it has been
shown that the ‘Sharkey’ mutations S418P and K441E
enhance the endonuclease activity further (47,48). For
this reason we introduced both sets of these mutations
into the FokI domains of R3, R4, L5 and L6 ZFNs
(designated enhanced ZFN, or eZFN) that were most
active in the episomal and genomic SSA assays. These
modiﬁcations signiﬁcantly increased the percentage of
cells that expressed EGFP in the genomic SSA assay
when compared to the same R3L5 (P=2.2E-7), R3L6
(P=5E-4), R4L5 (P=0.002), R4L6 (P=0.02) ZFNs
containing a wild-type FokI domain (Figure 2C). We
did not observe a signiﬁcant difference between cells trans-
fected with eZFN R3L5, R3L6, R4L5 or R4L6 in which
the percentage of cells that expressed GFP varied between
6.2% and 6.4%.
ZFN activity at the ROSA26 locus
The ZFNs that were active in the SSA assays were further
evaluated for activity at the endogenous target sequence
by the Surveyor assay (50). A double-strand break
induced by ZFNs is typically repaired by error-prone
NHEJ. The repaired DNA often contains small insertions
or deletions, designated ‘indels’, at the break site. These
indel mutations were detected by PCR ampliﬁcation of the
target site from genomic DNA and incubation of the
resulting product with the mismatch-sensitive Cel-I
nuclease (Figure 3A). The percentage of endogenous
gene modiﬁcation was calculated using image analysis of
polyacrylamide gels as previously described (50).
Neuro2A cells were transfected with the ZFN pairs
R3L4, R3L5, R3L6, R4L4, R4L5 and R4L6. After 3
days the genomic DNA was isolated and the Surveyor
assay was performed (Figure 3B). No gene modiﬁcation
was detected in cells electroporated with control plasmid,
whereas signiﬁcant levels of modiﬁcation were detected in
all samples treated with ZFNs. There was no signiﬁcant
difference in the activity of ZFN pairs containing R3 or
R4 arrays. However, the activity of ZFNs containing the
L4 array ( 10% indels) increased to  16% indels when
the L5 module was added, independent of the number of
modules in the right ZFN. Addition of the L6 module to
ZFN L5 slightly decreased the endonuclease activity of the
ZFNs at the endogenous locus between 1 and 2%, which
is within the variability of this assay. The rate of endogen-
ous allele modiﬁcation by the eZFNs with the R3L5,
R3L6, R4L5 and R4L6 zinc ﬁnger arrays was between
16 and 17%, indicating that the obligate heterodimers
with the Sharkey mutations may have slightly increased
the endonuclease activity of the FokI domains at the
genomic target site (Figure 3C). To conﬁrm the modiﬁca-
tion of the endogenous ROSA26 locus by ZFNs, the
target locus was ampliﬁed by PCR of the genomic DNA
from cells treated with the R4L6 eZFN and ligated
into a plasmid. Individual plasmids were screened by
digestion with XbaI, which cuts within the ZFN target
site, to identify plasmids containing indels. Plasmids that
were not cut by XbaI were sequenced to verify the
presence of indels resulting from error-prone repair of
the double-strand break induced by the endonuclease
activity of the ROSA26 ZFNs (Figure 3D).
Neuro2A cells were transfected with ROSA26 R4L6
eZFNs and genomic DNA was isolated at 16, 32, 48, 72
and 120h after transfection. The endonuclease activity of
the ZFNs can be readily detected at 16h (11% indels) and
reaches near maximal levels of activity of  18% at 32h.
The percentage of gene modiﬁcation remained effectively
constant for 5 days. The results demonstrated a
time-dependent increase in the endonuclease activity of
the ROSA26 ZFNs at the target site, which persists over
time indicating that this targeted genomic modiﬁcation is
well-tolerated by the cells (Figure 4A). The dependence of
ZFN dose on gene modiﬁcation was assessed by
electroporating 5, 10 or 20mg of each R4L6 eZFN into
Neuro2A cells. Genomic DNA was collected 72h after
electroporation. The rates of endogenous gene modiﬁca-
tion were 9, 14, and 17%, demonstrating a dose-
dependent effect of the amount of ZFN expression
vector delivered to the cells on endonuclease activity at
the target locus (Figure 4B).
Many cell type-dependent factors inﬂuence the activity
of ZFNs (34). The activity of the ROSA26 R4L6 eZFN
was tested in a panel of murine cell lines,
including NIH3T3 embryonic ﬁbroblasts, C2C12 skeletal
myoblasts, Neuro2A neuroblastoma cells, and primary
skeletal myoblasts (Figure 4C). Although the activity of
the ZFNs was highest in Neuro2A cells with rates of
endogenous gene modiﬁcation of 18%, substantial rates
of gene modiﬁcation were detected in NIH3T3 cells and
primary myoblasts (11%) and C2C12 cells (6.5%). These
results suggest that the ROSA26 ZFNs can facilitate cell
line engineering in a diverse variety of cell types.
Targeted gene addition at the ROSA26 locus
The endogenous cellular machinery can efﬁciently repair
DNA by homologous recombination (HR) at sites of a
double-strand break (8,9,23). For this reason, ZFNs are
valuable tools to promote gene insertion at speciﬁc
genomic target sites. To introduce DNA sequences at
the target site, a donor vector was assembled that
contains two 800bp homology arms adjacent to the
left and right of the ROSA26 target site separated by a
46bp multiple cloning site (MCS) (Figure 5A). Speciﬁc
integration of the MCS into the ROSA26 locus
was identiﬁed by PCR with primers that bind in the
MCS and in the ROSA26 genomic DNA beyond the
homology arms. Only speciﬁc integration events generate
a PCR product. No speciﬁc integration events were
detected following delivery of an empty vector, the
ROSA26 eZFNs, or the donor vector alone. However,
when the L6R4 eZFNs were transfected together with
the donor vector, the MCS derived from the donor
vector was integrated into the ROSA26 locus at the
3746 Nucleic Acids Research, 2012,Vol.40, No. 8target site (Figure 5B). This result was conﬁrmed by
sequencing the PCR product.
To examine the ability of various ZFN pairs to integrate
sequences of interest in the ROSA26 locus, Neuro2A cells
were electroporated with R3L4, R3L5, R3L6, R4L4,
R4L5 and R4L6 ZFNs and R3L5, R3L6, R4L5 and
R4L6 eZFNs together with the donor vector that
contains an MCS between the homology arms. Using
Figure 3. Activity of the ROSA26 ZFNs at the endogenous target locus. (A) Schematic representation of the Surveyor assay. Genomic DNA from
cells transfected with ZFNs is isolated and used in a PCR reaction that ampliﬁes wild-type DNA and DNA cleaved by the ZFNs and repaired by
error-prone non-homologous end joining (NHEJ). The PCR product is melted and reannealed to facilitate the formation of heteroduplexes, which
can be detected as cleaved fragments of the PCR product upon digestion with Cel-I nuclease. (B) Level of endogenous allele modiﬁcation induced by
ROSA26 ZFNs with a wild-type FokI domain. Neuro2A cells were transfected with ZFNs containing 3, 4, 5 or 6 modules in the left and right array.
After 3 days the genomic DNA was isolated and the Surveyor assay was performed. No gene modiﬁcation was detected in cells electroporated with
control plasmid, whereas signiﬁcant levels of modiﬁcation were detected in all samples treated with ZFNs. Although there was no signiﬁcant
difference in the activity of ZFN pairs containing R3 or R4 arrays by this assay, ZFN activity increases when the L5 module is added to the
L4 array. (C) Level of endogenous allele modiﬁcation induced by ROSA26 eZFNs. The level of endogenous allele modiﬁcation by the eZFNs was
signiﬁcantly higher than modiﬁcation by wild-type ZFNs regardless of the number of zinc ﬁnger modules in either array. (D) Sequences of indels at
the ROSA26 target site following ZFN-mediated cleavage and repair by NHEJ.
Figure 4. Levels of ROSA26 ZFN activity as a function of time, dose, and cell type. (A) Time-dependent activity of ROSA26 ZFNs. Neuro2A cells
were transfected with ROSA26 R4L6 eZFNs and genomic DNA was isolated at 16, 32, 48, 72 and 120h after transfection. The endonuclease activity
of the ZFNs was readily detected at 16h and reached near maximal levels of activity at 32h. The percentage of gene modiﬁcation remained
effectively constant for 5 days. (B) Dose-dependent activity of ROSA26 ZFNs. DNA was isolated from Neuro2A cells transfected with 5, 10 or
20mg of plasmid encoding ROSA26 ZFNs and the level of genomic modiﬁcation was measured by the Surveyor assay. Targeted DNA cleavage
increased with the dose of ROSA26 ZFN expression plasmid. (C) Cell type-dependent activity of ROSA26 ZFNs. The activity of the ROSA26 R4L6
eZFN was tested in a panel of murine cell lines, including NIH3T3 embryonic ﬁbroblasts, C2C12 skeletal myoblasts, Neuro2A neuroblastoma cells,
and primary skeletal myoblasts. The activity of the ZFNs was consistently highest in Neuro2A cells, however, signiﬁcant levels of gene modiﬁcation
were detected in all cell lines tested.
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locus beyond the homology arms, we demonstrated that
all the ZFN pairs built were effective at mediating inte-
gration of the MCS in the genomic DNA at the target site
(Figure 5C).
The efﬁciency of targeted integration driven by HR
decreases as the length of the inserted DNA sequence in-
creases (31). Therefore, to characterize the efﬁciency with
which the ROSA26 ZFNs facilitate addition of a complete
gene at this locus, a  1.6kb sequence consisting of an
expression cassette for a Zeocin
R-EGFP fusion protein
driven by a CMV promoter was inserted between the
homology arms of the donor vector described above.
The empty vector, R4L6 ROSA26 eZFNs alone, donor
vector alone, or donor vector together with the
L6R4 ROSA26 eZFNs were electroporated into
Neuro2A cells. Targeted gene addition was assayed by
PCR of the genomic DNA with primers that bind in the
Zeocin
R-EGFP expression cassette and in the ROSA26
locus beyond the homology arms. The transgene was
inserted correctly in the target site only when the donor
vector was delivered with the ZFNs (Figure 6A).
Sequencing of the PCR product conﬁrmed the expected
HR result.
Zeocin
R-EGFP gene expression in our donor vector is
driven by a CMV promoter and therefore EGFP can be
readily detected in samples electroporated with donor
vector regardless of the expression of the ROSA26
ZFNs. Because transient expression of EGFP is expected
to decay over time and only expression from donor
plasmid integrated in the genome will be sustained,
EGFP expression was measured by ﬂow cytometry over
25 days in cells transfected with donor vector only or with
donor vector and ZFNs to estimate the efﬁciency of trans-
gene integration (Figure 6B). The results show a rapid
decrease in the levels of transient protein expression
between days 8 and 11 in cells transfected with donor
vector only. At day 14 and afterward, expression of
EGFP was detectable in <1% of the cells. However, in
cells transfected with donor vector and ROSA26 ZFNs,
 10% of the cell population expressed EGFP after 25
days, conﬁrming that site-speciﬁc double-strand breaks
facilitate highly efﬁcient targeted integration of donor
sequences into the genome.
The Zeocin
R-EGFP transgene confers resistance to the
antibiotic Zeocin. Neuro2A cells transfected with the
donor vector alone or cotransfected with the donor
vector and R4L6 ROSA26 eZFNs were selected with
Zeocin. After 2 weeks, clonal populations were isolated
and analyzed for presence of the Zeocin
R-EGFP transgene
in the ROSA26 locus. All 12 clones contained the desired
integration event when the donor vector and the ZFNs
were cotransfected (Figure 6C), which is consistent with
the >10-fold increase in cells stably expressing EGFP
Figure 5. Targeted homologous recombination directed by ROSA26 ZFNs. (A) Schematic representation of targeted integration via homologous
recombination using ZFNs. The donor vector contains two 800bp arms of homology with the ROSA26 locus adjacent to the ZFN target site. Genes
of interest (GOI), such as the Zeocin
R-EGFP cassette (ZeoEGFP), can be cloned into the multiple cloning site (MCS) between the two homology
arms. When this vector is delivered together with the ZFNs, the endogenous repair mechanisms can use the donor vector as template to repair the
double-strand break. This will result in integration of the gene of interest into the genome at the ZFN target site. (B) Integration of a 45bp sequence
into the ROSA26 locus using the ROSA26 R4L6 eZFN. Neuro2A cells were electroporated with control DNA, with ROSA26 R4L6 eZFN, with an
empty donor vector alone or with ROSA26 R4L6 eZFN and the donor vector. PCR with primers that bind the MCS and the ROSA26 locus beyond
the homology arms was performed. No speciﬁc integration events were detected following delivery of an empty vector, the ROSA26 eZFNs, or the
donor vector alone. However when the ZFNs were transfected together with the donor vector, the MCS derived from the donor vector was
integrated into the ROSA26 locus at the target site. (C) Integration of a 45bp sequence into the ROSA26 locus using ZFNs of variably sized
zinc ﬁnger arrays. Neuro2A cells were electroporated with expression plasmids for eZFN pairs containing 3, 4, 5 or 6 modules in the left and right
arrays and the MCS donor vector. All the ZFN pairs were effective at mediating integration of the MCS into the genomic DNA at the correct target
site, as determined by PCR with primers that bind the MCS and the ROSA26 locus beyond the homology arms.
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R clones from cells
transfected with donor vector alone contained targeted
integration events, indicating these clones were the result
of random plasmid integration. To determine whether the
targeted clones were homozygous or heterozygous, PCR
was performed with primers that amplify a 621bp DNA
fragment in the wild-type ROSA26 locus surrounding the
ZFN target site. The presence of this PCR product
together with a targeted integration PCR product indi-
cates a heterozygous cell line. The results showed that
all 12 cell lines studied were heterozygous (Figure 6C).
Importantly, American Type Culture Collection (ATCC)
reports the Neuro2A cell line to be hyperploid with an
unstable karyotype. Consequently, it is likely that there
are more than two ROSA26 alleles within each genome
and the exact number of targeted alleles within each clone
cannot be determined by this assay.
Each of the 24 clonal cell lines was analyzed by ﬂow
cytometry to determine the levels of EGFP expression.
Clones derived from transfections with the donor vector
alone displayed highly variable levels of EGFP expression
between clones and within each clone, as demonstrated by
wide histograms (Figure 6D). This is likely the result of
chromosomal positional effects caused by random
plasmid integration. In fact, one clone was resistant to
Zeocin but did not express EGFP, indicating that only a
fragment of the expression cassette was integrated.
However, in the clones from cells treated with ZFNs and
expression vector, the levels of EGFP expression were
homogeneous between clones and less variable within a
clone, as demonstrated by narrow and uniform histograms
(Figure 6E). The dramatically reduced variability of gene
expression achieved by ZFN-mediated gene targeting was
quantiﬁed as a >2-fold decrease in the mean of the coefﬁ-
cient of variation of cellular ﬂuorescence intensity of each
clonal population and a >10-fold decrease in the standard
deviation of the coefﬁcient of variation for each clone
(Figure 6F). Additionally the coefﬁcient of variation of
the mean ﬂuorescence intensity of each clone decreased
from 0.76 to 0.43 when ZFNs were added. These results
Figure 6. Targeted integration of a Zeocin
R-EGFP expression cassette into the ROSA26 locus. (A) Integration of ZeoEGFP in the ROSA26 locus
using ROSA26 R4L6 eZFN in unselected populations. To determine whether the ROSA26 ZFNs facilitate targeted addition of larger expression
cassettes at this locus, a  1.6kb sequence consisting of a Zeocin
R-EGFP gene (ZeoEGFP) driven by a CMV promoter was inserted between the
homology arms of the donor vector. Control plasmid, ROSA26 R4L6 eZFN alone, donor vector alone, or donor vector together with the ROSA26
R4L6 eZFN were electroporated into Neuro2A cells. Targeted gene addition was tested using PCR of the genomic DNA with primers that bind in
the Zeo-EGFP expression cassette and genomic DNA in the ROSA26 locus beyond the homology arms. The transgene was inserted correctly in the
target site, as conﬁrmed using sequencing of the PCR product, only when the donor vector was delivered with the ZFNs. (B) Efﬁciency of
ZFN-mediated targeted gene addition. In cells transfected with only the donor vector, ZeoEGFP expression was detectable in less than 1% of
transfected cells by 14 days post-transfection. However,  10% of the cell population expressed EGFP after 25 days in cells transfected with donor
vector and the ROSA26 R4L6 eZFNs, representing sustained expression from integrated expression cassettes (ANOVA P=2E-4; Student’s t test
P=1E-4). (C) Clonal analysis of gene targeting by ROSA26 ZFNs. Neuro2A cells were transfected with the ZeoEGFP donor vector alone or
cotransfected with the donor vector and the ROSA26 R4L6 eZFNs. The cells were selected with Zeocin and clonal populations were isolated and
analyzed for presence of the ZeoEGFP transgene in the ROSA26 locus. All clones contained the desired integration event when the donor vector and
the ZFNs were cotransfected but not when the donor vector was delivered alone. Further analysis using PCR with primers that detect the wild-type
ROSA26 locus determined that the clones containing targeted ROSA26-ZeoEGFP integration also contained at least one wild-type allele. (D and E)
Expression of ZeoEGFP from the ROSA26 locus. To determine the levels of EGFP expressed from the ZeoEGFP transgene stably integrated into
the genome, the (D) 12 untargeted and (E) 12 targeted clonal cell lines were analyzed by ﬂow cytometry. Clones derived from transfections with the
donor vector alone expressed highly variable levels of EGFP. In contrast, the clones from cells treated with ZFNs and expression vector showed
relatively homogenous levels of EGFP expression. (F) Quantiﬁcation of variability of gene expression in untargeted and targeted clones. The reduced
variability of gene expression achieved by ZFN-mediated gene targeting was quantiﬁed as a decrease in the mean of the coefﬁcient of variation of
cellular ﬂuorescence intensity of each clonal population and a dramatic decrease in the standard deviation of the coefﬁcient of variation for each
clone (n=12, mean±SD).
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DISCUSSION
The use of cell lines with identical genetic content is
critical to ensuring uniform gene expression within a cell
population. Methods for obtaining these isogenic cell lines
are widely employed in basic science, biomedical research
and biotechnological applications such as biopharmaceut-
ical production. This is often achieved by random vector
integration into the genome, either by viral transduction
or plasmid transfection, and selection for clones that
stably express the transgene cassette. However, because
of highly variable levels of transgene expression following
random integration (Figure 6D), the laborious process of
screening clones for suitable expression levels is necessary.
Alternatively, several commercial systems are available for
targeted plasmid integration into mammalian genomes,
such as the Flp-In
TM and Jump-In
TM systems marketed
by Invitrogen which make use of the Flp recombinase (56)
and phiC31 integrase (57), respectively. Zinc ﬁnger recom-
binases have also been used for targeted plasmid integra-
tion in mammalian cells (58–60). However, all of these
approaches require that genomic landing pads containing
the recombinase and integrase target sites be
preintroduced into the genome. Therefore these systems
have not yet been used to target endogenous genomic
loci in otherwise unmodiﬁed cells. The ZFN technology
utilized in this study provides a general method for cell
line engineering that can be applied to any primary or
established murine cell line. The highly speciﬁc gene tar-
geting directed by the cellular HR machinery suggests that
screening for targeted integration events will be unneces-
sary in many cell types. This work offers a murine
analogue to previous protocols developed for similar
purposes targeting the AAVS1 locus in human cell
lines (32,34).
In addition to cell line engineering, gene targeting with
the ROSA26 ZFNs may be useful for in vivo applications
as well. A recent study demonstrated the efﬁcacy of gene
targeting in the liver of mice following in vivo administra-
tion of ZFNs and donor vectors (61). This study used
transgenic mice carrying a human gene sequence and
ZFNs that target this sequence. The ROSA26 ZFNs
described here may provide a method for in vivo gene tar-
geting of any mouse strain. This approach is valuable for
understanding gene function in the context of a living
organism and can be used as a preclinical model to
evaluate gene therapy strategies based on therapeutic
transgene integration at ‘safe harbor loci’ (32,34).
In this study, we developed several ZFNs containing
different number of zinc ﬁnger modules targeting the
ROSA26 locus in the mouse genome. Episomal and
genomic reporter assays of ZFN activity showed that
increasing the number of modules enhances the nuclease
activity of the ZFN pairs at the target site. More import-
antly, assays for DNA repair at the endogenous locus
demonstrated a correlation between additional modules
and enhanced activity. In general, we have observed a
common trend with ZFNs constructed with modular
assembly reagents (39,40) that ZFNs with three zinc ﬁnger
modules have little or no activity (unpublished results).
However, ZFN activity is dramatically enhanced by the
addition of a fourth, ﬁfth, or sometimes sixth module
(Figures 2B, C and 3C and unpublished results). The
results are consistent with a recent report using ZFNs
assembled by the same method (48). The addition of a
fourth zinc ﬁnger module also increases the activity of
zinc ﬁnger recombinases created by modular assembly
(58,62). In a small number of cases we have observed
that the addition of a ﬁfth or sixth zinc ﬁnger module
decreases overall ZFN activity (unpublished results), con-
sistent with another recent study (54). Collectively, these
results suggest that the number of modules on ZFN arrays
may be an underappreciated parameter in determining the
activity of modularly assembled ZFNs. A large scale study
of the role of module number on ZFN activity and speci-
ﬁcity is necessary to determine if these anecdotal observa-
tions are generally applicable to ZFN engineering by
modular assembly.
Many methods have been described for the design,
selection and assembly of zinc ﬁnger modules to
generate ZFNs targeted to loci of interest (18,36–43).
The modular assembly approach used here is particularly
straightforward and can be used in combination with an
online utility (39) to design ZFNs that can be synthesized
de novo or constructed by recombinant DNA technology
in <2 weeks (40). Other studies have reported a surpris-
ingly low success rate with this method when evaluating
only ZFNs consisting of three zinc ﬁnger modules (18,44),
although many retain their intended sequence speciﬁcity
(63). Therefore these studies are consistent with the results
reported here and in other work (48) that four zinc ﬁnger
modules are often necessary to generate functional ZFNs
by modular assembly. The effect of increasing zinc ﬁnger
module number on ZFN speciﬁcity and off-target activity
remains to be determined, but it is noteworthy that
many of the most active ZFNs in the published literature
consist of four to six zinc ﬁnger modules (34,61,64).
Collectively, all of these results are consistent with the
hypothesis that the balance between speciﬁcity and
afﬁnity is more important than the precise number of
zinc ﬁnger modules (54).
Our overall success rate in obtaining clones with
targeted integrations was highly variable among different
cell lines. Neuro2A cells appear to be particularly
amenable to ZFN-mediated genome editing, similar to
the highly efﬁcient ZFN-mediated gene targeting of
human DNA sequences routinely observed in K562 cells
(34). It is important to note that both the rates of NHEJ
and the efﬁciency of HR are cell type-speciﬁc. Although
all of the targeted Neuro2A clones contained the desired
integration event, in other cells lines the targeting fre-
quency was lower. The reason for these different results
is unclear; however the chromatin state, epigenetic effects,
cell cycle rates, and the status of the cellular to HR ma-
chinery are cell type-dependent factors that likely affect
ZFN-mediated gene targeting. Additionally, the frequency
of random donor vector integration varies dramatically
3750 Nucleic Acids Research, 2012,Vol.40, No. 8between cell types and affects the overall rate of gene
targeting.
This study describes the development, testing and val-
idation of several ZFN pairs and donor vectors to achieve
speciﬁc integration of transgenes in the mouse ROSA26
locus, where they are homogeneously and uniformly
expressed. We anticipate that this work will be relevant
for many varied applications in the ﬁelds of cell line and
mouse engineering and preclinical studies of gene and cell
therapy.
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